Also known as: ARTBIO
ARTBIO is a clinical-stage radiopharmaceutical company developing alpha radioligand therapies that pair lead-212 with ligands against tumor-specific targets. The company aims to create a new class of targeted cancer therapies while building distributed manufacturing capabilities.
The global radioligand therapy market is projected to grow from $2.6 billion in 2025 to $4.8 billion by 2030 at 13.1% CAGR, driven by FDA label expansions, earlier-line treatment positioning, and substantial private investment in isotope production infrastructure.
DelveInsight releases three separate pipeline reports covering metastatic prostate cancer (80+ companies, 85+ drugs), iPSC-derived NK cells (12+ companies, 15+ drugs), and interstitial lung diseases (120+ companies, 120+ drugs), highlighting recent regulatory approvals, trial launches, and emerging therapies.
